| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $1.9M | — |
| R&D Expense | $994K | -0.3% |
| SG&A Expense | $5.9M | +116.0% |
| Operating Income | -$4.9M | -32.7% |
| Net Income | -$3.9M | -14.1% |
| EPS (Basic) | -$0.55 | +71.4% |
| EPS (Diluted) | -$0.55 | +71.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $840K | — |
| Accounts Receivable | $76K | — |
| Current Assets | $12.6M | -25.1% |
| Total Assets | $13.4M | -21.2% |
| Current Liabilities | $681K | +69.5% |
| Total Liabilities | $681K | +69.5% |
| Stockholders' Equity | $13.1M | -21.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$3.9M | -17.5% |
| Investing Cash Flow | -$9.7M | — |
| Financing Cash Flow | $16.6M | +0.0% |